Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
暂无分享,去创建一个
A. Kastrati | J. Mehilli | J. Dirschinger | J. Pache | H. Schühlen | A. Schömig | K. Ulm | R. Wessely | N. von Beckerath | A. Dibra
[1] G. Stone,et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. , 2005, Journal of the American College of Cardiology.
[2] G. Breithardt,et al. Relationship of Late Loss in Lumen Diameter to Coronary Restenosis in Sirolimus-Eluting Stents , 2005, Circulation.
[3] A. Kastrati,et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. , 2005, JAMA.
[4] J. Moses,et al. Quantitative Assessment of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Native Coronary Arteries , 2004, Circulation.
[5] A. Kastrati,et al. Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel , 2004, Circulation.
[6] W. O’Neill,et al. Impact of Sirolimus-Eluting Stents on Outcome in Diabetic Patients: A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) Substudy , 2004, Circulation.
[7] A. Kastrati,et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. , 2004, The New England journal of medicine.
[8] G. Stone,et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.
[9] R. T. Hurst,et al. Increased Incidence of Coronary Atherosclerosis in Type 2 Diabetes Mellitus: Mechanisms and Management , 2003, Annals of Internal Medicine.
[10] Jeffrey W Moses,et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.
[11] M. Leon,et al. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors: combination therapy for the future. , 2003, American heart journal.
[12] J. Beckman,et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I , 2013, European heart journal.
[13] S. Silber,et al. Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions , 2003, Circulation.
[14] D. Faxon,et al. Clinical studies on coronary revascularization in patients with type 2 diabetes. , 2003, European heart journal.
[15] Patrick W Serruys,et al. New frontiers in cardiology: drug-eluting stents: Part I. , 2003, Circulation.
[16] R. Frye,et al. Gap Between Clinical Trials and Clinical Practice: Lessons From the Bypass Angioplasty Revascularization Investigation (BARI) , 2003, Circulation.
[17] R. D'Agostino,et al. Non‐inferiority trials: design concepts and issues – the encounters of academic consultants in statistics , 2002, Statistics in medicine.
[18] P. Serruys,et al. Angiographic Findings of the Multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): Sirolimus-Eluting Stents Inhibit Restenosis Irrespective of the Vessel Size , 2002, Circulation.
[19] J. Killian,et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. , 2002, Journal of the American College of Cardiology.
[20] P. Serruys,et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.
[21] R B D'Agostino,et al. Cardiovascular Risk Assessment Based on US Cohort Studies: Findings From a National Heart, Lung, and Blood Institute Workshop , 2001, Circulation.
[22] G. Stone,et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. , 1999, Circulation.
[23] T. Fleming,et al. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. , 1999, JAMA.
[24] R. Kuntz. Importance of considering atherosclerosis progression when choosing a coronary revascularization strategy: the diabetes-percutaneous transluminal coronary angioplasty dilemma. , 1999, Circulation.
[25] M. Hadamitzky,et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. , 1998, Journal of the American College of Cardiology.
[26] M. Leon,et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. , 1998, Journal of the American College of Cardiology.
[27] T. Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. , 1998, Lancet.
[28] E. Topol. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade , 1998, The Lancet.
[29] J. Isner,et al. The biology of restenosis. , 1997, Progress in cardiovascular diseases.
[30] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.
[31] Shein-Chung Chow,et al. Design and Analysis of Bioavailability and Bioequivalence Studies , 1994 .
[32] D. Baim,et al. Restenosis after Arterial Injury Caused by Coronary Stenting in Patients with Diabetes Mellitus , 1993, Annals of Internal Medicine.
[33] E J Topol,et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. , 1990, Circulation.
[34] J. Moses,et al. Sirolimus-eluting stents vs. standard stents in patients with stenosis in a native coronary artery , 2004 .
[35] Keith E. Muller,et al. Unified power analysis for t-tests through multivariate hypotheses. , 1993 .